


PRODUCT INFORMATION



Methylnaltrexone (bromide)

Item No. 24072

CAS Registry No.: 73232-52-7
Formal Name: 17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxy-17-methyl-6-oxo-morphinanium, monobromide
Synonyms: MRZ 2663BR, Naltrexone methylbromide
MF: C₂₁H₂₆NO₄ • Br
FW: 436.3
Purity: \geq 95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Methylnaltrexone (bromide) is supplied as a crystalline solid. Aqueous solutions of methylnaltrexone (bromide) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of methylnaltrexone (bromide) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Methylnaltrexone is a quaternary positively-charged form of naltrexone (Item No. 15520) that does not cross the blood brain barrier. It is a peripherally restricted μ -opioid receptor antagonist with a K_i value of 10 nM for human recombinant receptors expressed in CHO-K1 cells and IC_{50} values of 130.7 and 0.43 nM in rat brain membranes prepared with sodium chloride or water, respectively.¹ Methylnaltrexone is selective for μ -opioid receptors over δ - and κ -opioid receptors (K_i s = 630.95 and 31.62 nM, respectively). It inhibits contractions evoked by electrical field stimulation (EFS) in ileum isolated from morphine-naïve guinea pigs and dose-dependently decreases spontaneous mechanical activity in ileum isolated from morphine-treated guinea pigs when administered at doses of 1 and 10 μ M.² It does not inhibit heroin self-administration in rats and does not induce withdrawal syndrome in morphine-dependent rhesus monkeys when administered at doses up to 32 mg/kg.^{1,3} Formulations containing methylnaltrexone have been used in the treatment of opioid-induced constipation.

References

1. Valentino, R.J., Katz, J.L., Medzihradsky, F., *et al.* Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. *Life Sci.* **32(25)**, 2887-2896 (1983).
2. Beattie, D.T., Cheruvu, M., Mai, N., *et al.* The *in vitro* pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. *Naunyn Schmiedeberg's Arch. Pharmacol.* **375(3)**, 205-220 (2007).
3. Koob, G.F., Pettit, H.O., Ettenberg, A., *et al.* Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat. *J. Pharm. Exp. Ther.* **229(2)**, 481-486 (1984).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM